Kura Oncology reported its third‑quarter 2025 financial results for the nine‑month period ended September 30, 2025.
Revenue for the quarter was $20.75 million, a sharp decline from the $85.45 million consensus estimate and from $20.8 million in Q3 2024. Net loss was $74.12 million, up from $54.4 million in the same quarter last year, with a basic and diluted loss per share of $0.85 versus $0.63 in Q3 2024.
For the nine months ended September 30, 2025, revenue totaled $20.75 million, down from $20.8 million in the same period 2024. Net loss for the nine‑month period was $197.67 million, compared with $154.77 million in 2024, and basic and diluted loss per share was $2.26 versus $1.80 in 2024.
The company attributed the widened loss to higher research and development and general and administrative expenses, while milestone payments from its collaboration with Kyowa Kirin provided $60 million in cash inflows.
Cash, cash equivalents, and short‑term investments stood at $609.7 million as of September 30, 2025, giving the company a runway into 2027.
Management highlighted progress in the ziftomenib program, noting that the New Drug Application is under FDA Priority Review with a PDUFA date of November 30, 2025, and that milestone payments of $30 million were received from Kyowa Kirin for the KOMET‑017 trial.
The company did not provide new guidance for the remainder of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.